deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03712878

2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies

A 2 Step Approach to Matched Related Hematopoietic Stem Cell Transplantation for Patients With Hematological Malignancies-5+5 Dosing

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Conditions Hematopoietic and Lymphoid Cell Neoplasm
Interventions Allogeneic Hematopoietic Stem Cell Transplantation Cyclophosphamide Donor Lymphocyte Infusion Mycophenolate Mofetil Tacrolimus Total-Body Irradiation
Updated 13 times since 2018 Last updated: Aug 20, 2025 Started: Sep 19, 2018 Primary completion: Mar 19, 2025 Completion: Mar 19, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hematopoietic and Lymphoid Cell Neoplasm and is currently completed. Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University leads this study, which shows 13 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Nov 2018 – ~Mar 2019 · 4 months · monthly snapshot~Mar 2019 – ~Apr 2020 · 13 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Aug 2023 · 11 months · monthly snapshot~Aug 2023 – ~Apr 2024 · 8 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshot

Change History

13 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE2

  2. Sep 2025 — Feb 2026 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Feb 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 8 earlier versions

  1. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Aug 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2022 — Aug 2023 [monthly]

    Recruiting PHASE2

  4. Sep 2021 — Sep 2022 [monthly]

    Recruiting PHASE2

  5. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  6. Apr 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  7. Mar 2019 — Apr 2020 [monthly]

    Recruiting PHASE2

  8. Nov 2018 — Mar 2019 [monthly]

    Recruiting PHASE2

    First recorded

Sep 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Data source: Thomas Jefferson University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations